Aprea Therapeutics (APRE.Q) today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. “The…
Latest News
Are stock markets about to crash hard?
Revive Therapeutics (RVV.CN) announces FDA acceptance of meeting request
Top 5 Gainers and Losers: LAC.TO, WEED.TO, OML.V
BC Bud Corp (BCBC.C) breathes new life into the cannabis space, up 3x in two months
Top 5 Gainers and Losers: TMQ.TO, GLM.CN, AGMR.V
Standard Uranium (STND.V) reports on exploration at Sun Dog Project